Homologous recombination deficiency testing in first-line ovarian cancer

Ann Oncol. 2022 Mar;33(3):231-233. doi: 10.1016/j.annonc.2021.12.013. Epub 2022 Jan 8.

Authors

K N Moore¹, A du Bois²

Affiliations

¹ Department of Obstetrics and Gynecology, Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, USA. Electronic address: [email protected].
² Department of Gynecology & Gynecologic Oncology, Evangelische Kliniken Essen Mitte (KEM), Essen, Germany.

PMID: 35017033
DOI: 10.1016/j.annonc.2021.12.013

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Ovarian Epithelial
Homologous Recombination
Humans
Ovarian Neoplasms* / diagnosis
Ovarian Neoplasms* / genetics